Options
2026
Letter to the Editor
Title
Chronic Spontaneous Urticaria Endotypes: Exploratory Proteomic Analysis in the Benralizumab ARROYO Study
Abstract
Full details of the ARROYO study have been previously published [5]. Briefly, adults with CSU refractory to standard-of-care treatment received second generation H 1-antihistamines during a 10day to 4-week run-in period, after which eligible patients were randomized to add-on subcutaneous benralizumab (30 mg Q4W This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Author(s)
Open Access
File(s)
Rights
CC BY 4.0: Creative Commons Attribution
Additional link
Language
English